Answers are grounded in this paper and cite their sources.
Demonstrates improved complete response rates in bladder cancer patients, suggesting a new standard in therapy.
The FDA approval of the gemcitabine intravesical system (Inlexzo/TAR-200) marks a breakthrough for BCG-unresponsive NMIBC with CIS. This novel drug-device combination enables sustained intravesical chemotherapy, achieving high complete response rates with acceptable safety. It represents a paradigm shift in bladder-sparing therapy, though long-term outcomes and accessibility remain critical considerations.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: